Switch theme
Sign up to access all valuation multiples
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
1982
5.5K+
LTM Revenue $451M
LTM EBITDA $94.3M
$560M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mega Lifesciences has a last 12-month revenue (LTM) of $451M and a last 12-month EBITDA of $94.3M.
In the most recent fiscal year, Mega Lifesciences achieved revenue of $468M and an EBITDA of $81.5M.
Mega Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mega Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $451M | XXX | $468M | XXX | XXX | XXX |
| Gross Profit | $227M | XXX | $236M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $94.3M | XXX | $81.5M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $87.8M | XXX | $103M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $62.5M | XXX | $61.3M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mega Lifesciences's stock price is THB 25 (or $1).
Mega Lifesciences has current market cap of THB 21.8B (or $664M), and EV of THB 18.4B (or $560M).
See Mega Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $560M | $664M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mega Lifesciences has market cap of $664M and EV of $560M.
Mega Lifesciences's trades at 1.2x EV/Revenue multiple, and 6.9x EV/EBITDA.
Equity research analysts estimate Mega Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mega Lifesciences has a P/E ratio of 10.6x.
See valuation multiples for Mega Lifesciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $664M | XXX | $664M | XXX | XXX | XXX |
| EV (current) | $560M | XXX | $560M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 6.4x | XXX | 5.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.6x | XXX | 10.8x | XXX | XXX | XXX |
| EV/FCF | 8.4x | XXX | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMega Lifesciences's last 12 month revenue growth is -4%
Mega Lifesciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $24K for the same period.
Mega Lifesciences's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mega Lifesciences's rule of X is 11% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mega Lifesciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 12% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mega Lifesciences acquired XXX companies to date.
Last acquisition by Mega Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Mega Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mega Lifesciences founded? | Mega Lifesciences was founded in 1982. |
| Where is Mega Lifesciences headquartered? | Mega Lifesciences is headquartered in Thailand. |
| How many employees does Mega Lifesciences have? | As of today, Mega Lifesciences has 5.5K+ employees. |
| Who is the CEO of Mega Lifesciences? | Mega Lifesciences's CEO is Mr. Vivek Dhawan. |
| Is Mega Lifesciences publicy listed? | Yes, Mega Lifesciences is a public company listed on BKK. |
| What is the stock symbol of Mega Lifesciences? | Mega Lifesciences trades under MEGA ticker. |
| When did Mega Lifesciences go public? | Mega Lifesciences went public in 2013. |
| Who are competitors of Mega Lifesciences? | Similar companies to Mega Lifesciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mega Lifesciences? | Mega Lifesciences's current market cap is $664M |
| What is the current revenue of Mega Lifesciences? | Mega Lifesciences's last 12 months revenue is $451M. |
| What is the current revenue growth of Mega Lifesciences? | Mega Lifesciences revenue growth (NTM/LTM) is -4%. |
| What is the current EV/Revenue multiple of Mega Lifesciences? | Current revenue multiple of Mega Lifesciences is 1.2x. |
| Is Mega Lifesciences profitable? | Yes, Mega Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mega Lifesciences? | Mega Lifesciences's last 12 months EBITDA is $94.3M. |
| What is Mega Lifesciences's EBITDA margin? | Mega Lifesciences's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Mega Lifesciences? | Current EBITDA multiple of Mega Lifesciences is 5.9x. |
| What is the current FCF of Mega Lifesciences? | Mega Lifesciences's last 12 months FCF is $66.3M. |
| What is Mega Lifesciences's FCF margin? | Mega Lifesciences's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Mega Lifesciences? | Current FCF multiple of Mega Lifesciences is 8.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
